Eisai sees potential of new Alzheimer's drug but costs remain concern

Eisai Co. CEO Haruo Naito said Wednesday a new drug for Alzheimer's disease it has developed with U.S. firm Biogen Inc. has the potential to become a "blockbuster" product.The approval by the U.S. Food and Drug Administration on Monday of the drug Aduhelm raised hopes for the treatment of Alzheimer's disease. But concern remains about higher medical costs as a patient would be charged $56,000 a year.Speaking in an online press conference, Naito said the pricing of the drug should reflect multiple factors, such as the impact on the families of patients taking it. "We believe it has the pote…READ FULL ARTICLE